Skip to main content
PMC home page
Proceedings of the Royal Society B: Biological Sciences logoLink to Proceedings of the Royal Society B: Biological Sciences
. 2000 Jan 22;267(1439):183–189. doi: 10.1098/rspb.2000.0985

Intra-host competition between nef-defective escape mutants and wild-type human immunodeficiency virus type 1.

H K Altes 1, V A Jansen 1
PMCID: PMC1690508  PMID: 10687825

Abstract

Various forms of nef genes with deletions at conserved positions along the sequence have been reported to persist in human immunodeficiency virus type 1 infected patients. We investigate the forces maintaining such variants in the proviral population. The main selection pressures are preservation of function and host immune response. The crippled Nef protein might have fewer epitopes, and as such be less visible to the specific immune response, but it will lose some function. Does a trade-off between avoidance of the immune response and loss of function explain the dynamics of the crippled virus found in the patients? To answer this question, we formulated a deterministic model of the virus-host interactions. We found that when the crippled protein presents few epitopes and suffers little loss of function, the two viral types can coexist. Otherwise, the wild-type comes to prevail. The mutant form might initially dominate, but as the selective pressure by the CD84+ T cells decreases over the course of infection, the advantage for the crippled form of losing epitopes disappears. Hence, we go from a situation of coexistence of wild-type and mutant, to a situation of only full-length nef. The results are discussed in the context of the suggested use of live attenuated vaccines having deletions in nef.

Full Text

The Full Text of this article is available as a PDF (283.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baba T. W., Jeong Y. S., Pennick D., Bronson R., Greene M. F., Ruprecht R. M. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science. 1995 Mar 24;267(5205):1820–1825. doi: 10.1126/science.7892606. [DOI] [PubMed] [Google Scholar]
  2. Baba T. W., Liska V., Khimani A. H., Ray N. B., Dailey P. J., Penninck D., Bronson R., Greene M. F., McClure H. M., Martin L. N. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med. 1999 Feb;5(2):194–203. doi: 10.1038/5557. [DOI] [PubMed] [Google Scholar]
  3. Baur A. S., Sawai E. T., Dazin P., Fantl W. J., Cheng-Mayer C., Peterlin B. M. HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity. 1994 Aug;1(5):373–384. doi: 10.1016/1074-7613(94)90068-x. [DOI] [PubMed] [Google Scholar]
  4. Berkhout B., Verhoef K., van Wamel J. L., Back N. K. Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J Virol. 1999 Feb;73(2):1138–1145. doi: 10.1128/jvi.73.2.1138-1145.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Berry R. M., Nowak M. A. Defective escape mutants of HIV. J Theor Biol. 1994 Dec 21;171(4):387–395. doi: 10.1006/jtbi.1994.1242. [DOI] [PubMed] [Google Scholar]
  6. Bonhoeffer S., Nowak M. A. Can live attenuated virus work as post-exposure treatment? Immunol Today. 1995 Mar;16(3):131–135. doi: 10.1016/0167-5699(95)80129-4. [DOI] [PubMed] [Google Scholar]
  7. Chun T. W., Stuyver L., Mizell S. B., Ehler L. A., Mican J. A., Baseler M., Lloyd A. L., Nowak M. A., Fauci A. S. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193–13197. doi: 10.1073/pnas.94.24.13193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Collins K. L., Chen B. K., Kalams S. A., Walker B. D., Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. 1998 Jan 22;391(6665):397–401. doi: 10.1038/34929. [DOI] [PubMed] [Google Scholar]
  9. Culmann-Penciolelli B., Lamhamedi-Cherradi S., Couillin I., Guegan N., Levy J. P., Guillet J. G., Gomard E. Identification of multirestricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein. J Virol. 1994 Nov;68(11):7336–7343. doi: 10.1128/jvi.68.11.7336-7343.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Culmann-Penciolelli B., Lamhamedi-Cherradi S., Couillin I., Guegan N., Levy J. P., Guillet J. G., Gomard E. Identification of multirestricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein. J Virol. 1995 Jan;69(1):618–618. [PMC free article] [PubMed] [Google Scholar]
  11. Daniel M. D., Kirchhoff F., Czajak S. C., Sehgal P. K., Desrosiers R. C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992 Dec 18;258(5090):1938–1941. doi: 10.1126/science.1470917. [DOI] [PubMed] [Google Scholar]
  12. Deacon N. J., Tsykin A., Solomon A., Smith K., Ludford-Menting M., Hooker D. J., McPhee D. A., Greenway A. L., Ellett A., Chatfield C. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1995 Nov 10;270(5238):988–991. doi: 10.1126/science.270.5238.988. [DOI] [PubMed] [Google Scholar]
  13. Diekmann O., Heesterbeek J. A., Metz J. A. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. J Math Biol. 1990;28(4):365–382. doi: 10.1007/BF00178324. [DOI] [PubMed] [Google Scholar]
  14. Dyer W. B., Ogg G. S., Demoitie M. A., Jin X., Geczy A. F., Rowland-Jones S. L., McMichael A. J., Nixon D. F., Sullivan J. S. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. J Virol. 1999 Jan;73(1):436–443. doi: 10.1128/jvi.73.1.436-443.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Farthing C. F., Sullivan J. L. SIV vaccine for AIDS. Science. 1998 Jan 2;279(5347):14–15. doi: 10.1126/science.279.5347.10i. [DOI] [PubMed] [Google Scholar]
  16. Fisher A. G., Ensoli B., Looney D., Rose A., Gallo R. C., Saag M. S., Shaw G. M., Hahn B. H., Wong-Staal F. Biologically diverse molecular variants within a single HIV-1 isolate. Nature. 1988 Aug 4;334(6181):444–447. doi: 10.1038/334444a0. [DOI] [PubMed] [Google Scholar]
  17. Frost S. D., McLean A. R. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS. 1994 Mar;8(3):323–332. doi: 10.1097/00002030-199403000-00005. [DOI] [PubMed] [Google Scholar]
  18. Geleziunas R., Miller M. D., Greene W. C. Unraveling the function of HIV type 1 Nef. AIDS Res Hum Retroviruses. 1996 Nov 20;12(17):1579–1582. doi: 10.1089/aid.1996.12.1579. [DOI] [PubMed] [Google Scholar]
  19. Gerrish P. J., Lenski R. E. The fate of competing beneficial mutations in an asexual population. Genetica. 1998;102-103(1-6):127–144. [PubMed] [Google Scholar]
  20. Gibbs J. S., Regier D. A., Desrosiers R. C. Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses. 1994 May;10(5):607–616. doi: 10.1089/aid.1994.10.607. [DOI] [PubMed] [Google Scholar]
  21. Goulder P. J., Edwards A., Phillips R. E., McMichael A. J. Identification of a novel HLA-A24-restricted cytotoxic T-lymphocyte epitope within HIV-1 Nef. AIDS. 1997 Dec;11(15):1883–1884. doi: 10.1097/00002030-199715000-00015. [DOI] [PubMed] [Google Scholar]
  22. Goulder P. J., Edwards A., Phillips R. E., McMichael A. J. Identification of a novel HLA-B*2705-restricted cytotoxic T-lymphocyte epitope within a conserved region of HIV-1 Nef. AIDS. 1997 Mar 15;11(4):536–538. [PubMed] [Google Scholar]
  23. Greenough T. C., Sullivan J. L., Desrosiers R. C. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med. 1999 Jan 21;340(3):236–237. doi: 10.1056/NEJM199901213400314. [DOI] [PubMed] [Google Scholar]
  24. Hahn B. H., Shaw G. M., Taylor M. E., Redfield R. R., Markham P. D., Salahuddin S. Z., Wong-Staal F., Gallo R. C., Parks E. S., Parks W. P. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science. 1986 Jun 20;232(4757):1548–1553. doi: 10.1126/science.3012778. [DOI] [PubMed] [Google Scholar]
  25. Harris M. From negative factor to a critical role in virus pathogenesis: the changing fortunes of Nef. J Gen Virol. 1996 Oct;77(Pt 10):2379–2392. doi: 10.1099/0022-1317-77-10-2379. [DOI] [PubMed] [Google Scholar]
  26. Haydon D. T., Woolhouse M. E. Immune avoidance strategies in RNA viruses: fitness continuums arising from trade-offs between immunogenicity and antigenic variability. J Theor Biol. 1998 Aug 21;193(4):601–612. doi: 10.1006/jtbi.1998.0726. [DOI] [PubMed] [Google Scholar]
  27. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  28. Hofbauer J., Sigmund K. On the stabilizing effect of predators and competitors on ecological communities. J Math Biol. 1989;27(5):537–548. doi: 10.1007/BF00288433. [DOI] [PubMed] [Google Scholar]
  29. Holmes E. C., de A Zanotto P. M. Genetic drift of human immunodeficiency virus type 1? J Virol. 1998 Jan;72(1):886–887. [PMC free article] [PubMed] [Google Scholar]
  30. Igarashi T., Kuwata T., Yamamoto H., Moriyama H., Ui M., Miyazaki Y., Hayami M. Infectivity and immunogenicity of SIVmac/HIV-1 chimeric viruses (SHIVs) with deletions in two or three genes (vpr, nef and vpx). Microbiol Immunol. 1998;42(1):71–74. doi: 10.1111/j.1348-0421.1998.tb01973.x. [DOI] [PubMed] [Google Scholar]
  31. Kestler H. W., 3rd, Ringler D. J., Mori K., Panicali D. L., Sehgal P. K., Daniel M. D., Desrosiers R. C. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell. 1991 May 17;65(4):651–662. doi: 10.1016/0092-8674(91)90097-i. [DOI] [PubMed] [Google Scholar]
  32. Kirchhoff F., Greenough T. C., Brettler D. B., Sullivan J. L., Desrosiers R. C. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med. 1995 Jan 26;332(4):228–232. doi: 10.1056/NEJM199501263320405. [DOI] [PubMed] [Google Scholar]
  33. Kirchhoff F., Greenough T. C., Hamacher M., Sullivan J. L., Desrosiers R. C. Activity of human immunodeficiency virus type 1 promoter/TAR regions and tat1 genes derived from individuals with different rates of disease progression. Virology. 1997 Jun 9;232(2):319–331. doi: 10.1006/viro.1997.8586. [DOI] [PubMed] [Google Scholar]
  34. Koenig S., Conley A. J., Brewah Y. A., Jones G. M., Leath S., Boots L. J., Davey V., Pantaleo G., Demarest J. F., Carter C. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med. 1995 Apr;1(4):330–336. doi: 10.1038/nm0495-330. [DOI] [PubMed] [Google Scholar]
  35. Krakauer D. C., Nowak M. T-cell induced pathogenesis in HIV: bystander effects and latent infection. Proc Biol Sci. 1999 May 22;266(1423):1069–1075. doi: 10.1098/rspb.1999.0745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Learmont J. C., Geczy A. F., Mills J., Ashton L. J., Raynes-Greenow C. H., Garsia R. J., Dyer W. B., McIntyre L., Oelrichs R. B., Rhodes D. I. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med. 1999 Jun 3;340(22):1715–1722. doi: 10.1056/NEJM199906033402203. [DOI] [PubMed] [Google Scholar]
  37. Mariani R., Kirchhoff F., Greenough T. C., Sullivan J. L., Desrosiers R. C., Skowronski J. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol. 1996 Nov;70(11):7752–7764. doi: 10.1128/jvi.70.11.7752-7764.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Mariani R., Skowronski J. CD4 down-regulation by nef alleles isolated from human immunodeficiency virus type 1-infected individuals. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5549–5553. doi: 10.1073/pnas.90.12.5549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. McLean A. R., Nowak M. A. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS. 1992 Jan;6(1):71–79. doi: 10.1097/00002030-199201000-00009. [DOI] [PubMed] [Google Scholar]
  40. Miller M. D., Greene W. C. Is the Nef protein of HIV-1 required for pathogenesis? Trends Microbiol. 1996 May;4(5):171–173. doi: 10.1016/0966-842x(96)30016-4. [DOI] [PubMed] [Google Scholar]
  41. Nowak M. A., Bonhoeffer S., Shaw G. M., May R. M. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol. 1997 Jan 21;184(2):203–217. doi: 10.1006/jtbi.1996.0307. [DOI] [PubMed] [Google Scholar]
  42. Nowak M. A., May R. M., Phillips R. E., Rowland-Jones S., Lalloo D. G., McAdam S., Klenerman P., Köppe B., Sigmund K., Bangham C. R. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature. 1995 Jun 15;375(6532):606–611. doi: 10.1038/375606a0. [DOI] [PubMed] [Google Scholar]
  43. Nowak M. A., McLean A. R. A mathematical model of vaccination against HIV to prevent the development of AIDS. Proc Biol Sci. 1991 Nov 22;246(1316):141–146. doi: 10.1098/rspb.1991.0136. [DOI] [PubMed] [Google Scholar]
  44. Ostrowski M. A., Krakauer D. C., Li Y., Justement S. J., Learn G., Ehler L. A., Stanley S. K., Nowak M., Fauci A. S. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J Virol. 1998 Oct;72(10):7772–7784. doi: 10.1128/jvi.72.10.7772-7784.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996 Mar 15;271(5255):1582–1586. doi: 10.1126/science.271.5255.1582. [DOI] [PubMed] [Google Scholar]
  46. Piguet V., Trono D. The Nef protein of primate lentiviruses. Rev Med Virol. 1999 Apr-Jun;9(2):111–120. doi: 10.1002/(sici)1099-1654(199904/06)9:2<111::aid-rmv245>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  47. Preston B. D., Poiesz B. J., Loeb L. A. Fidelity of HIV-1 reverse transcriptase. Science. 1988 Nov 25;242(4882):1168–1171. doi: 10.1126/science.2460924. [DOI] [PubMed] [Google Scholar]
  48. Price D. A., Goulder P. J., Klenerman P., Sewell A. K., Easterbrook P. J., Troop M., Bangham C. R., Phillips R. E. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1890–1895. doi: 10.1073/pnas.94.5.1890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Ratner L., Niederman T. M. Nef. Curr Top Microbiol Immunol. 1995;193:169–208. doi: 10.1007/978-3-642-78929-8_10. [DOI] [PubMed] [Google Scholar]
  50. Roberts J. D., Bebenek K., Kunkel T. A. The accuracy of reverse transcriptase from HIV-1. Science. 1988 Nov 25;242(4882):1171–1173. doi: 10.1126/science.2460925. [DOI] [PubMed] [Google Scholar]
  51. Saag M. S., Hahn B. H., Gibbons J., Li Y., Parks E. S., Parks W. P., Shaw G. M. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature. 1988 Aug 4;334(6181):440–444. doi: 10.1038/334440a0. [DOI] [PubMed] [Google Scholar]
  52. Salvi R., Garbuglia A. R., Di Caro A., Pulciani S., Montella F., Benedetto A. Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. J Virol. 1998 May;72(5):3646–3657. doi: 10.1128/jvi.72.5.3646-3657.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Schwartz D. H., Viscidi R., Laeyendecker O., Song H., Ray S. C., Michael N. Predominance of defective proviral sequences in an HIV + long-term non-progressor. Immunol Lett. 1996 Jun;51(1-2):3–6. doi: 10.1016/0165-2478(96)02547-3. [DOI] [PubMed] [Google Scholar]
  54. Shugars D. C., Smith M. S., Glueck D. H., Nantermet P. V., Seillier-Moiseiwitsch F., Swanstrom R. Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo. J Virol. 1993 Aug;67(8):4639–4650. doi: 10.1128/jvi.67.8.4639-4650.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Spina C. A., Kwoh T. J., Chowers M. Y., Guatelli J. C., Richman D. D. The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med. 1994 Jan 1;179(1):115–123. doi: 10.1084/jem.179.1.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Stahl-Hennig C., Dittmer U., Nisslein T., Pekrun K., Petry H., Jurkiewicz E., Fuchs D., Wachter H., Rud E. W., Hunsmann G. Attenuated SIV imparts immunity to challenge with pathogenic spleen-derived SIV but cannot prevent repair of the nef deletion. Immunol Lett. 1996 Jun;51(1-2):129–135. doi: 10.1016/0165-2478(96)02567-9. [DOI] [PubMed] [Google Scholar]
  57. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]
  58. Whatmore A. M., Cook N., Hall G. A., Sharpe S., Rud E. W., Cranage M. P. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol. 1995 Aug;69(8):5117–5123. doi: 10.1128/jvi.69.8.5117-5123.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Wodarz D., Nowak M. A. The effect of different immune responses on the evolution of virulent CXCR4-tropic HIV. Proc Biol Sci. 1998 Nov 22;265(1411):2149–2158. doi: 10.1098/rspb.1998.0552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Wyand M. S., Manson K. H., Garcia-Moll M., Montefiori D., Desrosiers R. C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol. 1996 Jun;70(6):3724–3733. doi: 10.1128/jvi.70.6.3724-3733.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Xu X. N., Screaton G. R., Gotch F. M., Dong T., Tan R., Almond N., Walker B., Stebbings R., Kent K., Nagata S. Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med. 1997 Jul 7;186(1):7–16. doi: 10.1084/jem.186.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary data file
10687825s01.pdf (58.3KB, pdf)

Articles from Proceedings of the Royal Society B: Biological Sciences are provided here courtesy of The Royal Society

RESOURCES